# Harmonization and standardization of personalized oncology care within the German network for personalized medicine (DNPM): methods of a controlled observational study employing an adapted stepped-wedge design

**Authors:** Antonia Bauer, Sebastian Himmler, Nisar Malek, Lisa-Marie Brenner, Yvonne Möller, Stephanie Vigier, Markus Buchner, Leonie Sundmacher, Stefanie Joos, Peter Martus

PMC · DOI: 10.3389/frhs.2025.1684984 · Frontiers in Health Services · 2026-01-02

## TL;DR

This study evaluates how to standardize personalized cancer care across German hospitals using a specific study design and mixed methods.

## Contribution

The paper introduces a harmonized approach to personalized oncology care using a modified stepped-wedge design across multiple German hospitals.

## Key findings

- The study tracks changes in patient management through molecular tumor board decisions across three tiers.
- A mixed-methods approach is used to assess patient and staff satisfaction and the quality of harmonized care.
- Health economic outcomes like healthcare costs and quality of life are evaluated despite limitations in data availability.

## Abstract

The goal of personalized medicine (PM) is to provide tailored diagnostics and therapies for individual patients, primarily in oncology. However, significant regional disparities exist in its implementation. The Deutsches Netzwerk für Personalisierte Medizin (DNPM; German Network for Personalized Medicine) project aims to harmonize and network the implementation of PM in Germany.

The DNPM project is evaluated as a Hybrid Type 3 implementation study using a non-randomized, modified stepped-wedge design. Twenty-one university hospital sites across Germany will transition from standard, non-harmonized care to a harmonized personalized medicine intervention at different time points, based on administrative readiness indicated by certification. The primary outcome is change in patient management due to molecular tumor board (MTB) decisions, assessed on three tiers using prospectively collected primary data entered by clinical staff: (1) number of patients with access to an MTB, (2) proportion with revised diagnostic or therapeutic recommendations, and (3) proportion with implemented changes. Therefore, the study aims to include 4,807 patients (intervention group: 3.507). A mixed-methods approach is employed to evaluate further aspects of the implementation process including patient and staff satisfaction, perceived quality of care, and the degree of harmonization and collaboration within the network. Health economic outcomes include health-related quality of life, healthcare utilization costs, and intervention-related costs.

The study's wide range of outcome parameters and mixed-methods approach yield robust results for implementation insights. A limitation of the study design is the lack of a clear cutoff for transitioning from the control to the intervention group and the lack of randomization. Additionally, the health economic evaluation is limited by the absence of health insurance claims data, as no insurance company is involved in the project.

This trial is registered with the German Clinical Trials Register (DRKS) under the trial number DRKS00031622 (registration date: 23 May 2023)

## Full-text entities

- **Diseases:** tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12808450/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC12808450/full.md

---
Source: https://tomesphere.com/paper/PMC12808450